ALSO NOTED: Abraxis seeks FDA approval; Xanthus licenses cancer therapies;and much more...

> Abraxis BioScience is seeking FDA approval to widen the use of Abraxane in breast cancer patients without a new study. Report

> Xanthus Pharmaceuticals has licensed a group of cancer targets from Schering. Report

> Taro Pharmaceutical has received FDA approval of a generic epilepsy therapy. Report

> Thomas, McNerny has closed a $375 million life science fund. Release

> Wisconsin Republican gubernatorial candidate Mark Green is promising to put up $25 million to advance new research into creating embryonic stem cell lines without destroying embryos. The position is intended to undercut his Democratic opponent's stand in favor of embryonic stem cell research. Report

> ESBATech, a developer of antibody fragment therapeutics, today announced the spin-out of its small molecule inhibitor programs to form a new company, Oncalis. Release

> GlaxoSmithKline has won a ruling that allows it to restrict drug supplies to Greece as it fights wholesalers who buy drugs cheaply in one European country and sell it in another at a profit. Report

> The FDA has issued an approval letter for Cardinal Health's new sterile facility in North Raleigh, N.C. to manufacture Panhematin, an Ovation biologic therapy used to treat acute porphyria, a rare genetic disorder. Release

And Finally... The threat of cardiovascular diseases is often ignored around the world. Article

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.